This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West
Mark Your Calendar for BPI US West 2024!
March 11-14, 2024Town and Country Resort, San Diego

Tiago Matos
Associate Principal Scientist at Merck


Tiago Matos is a Portuguese scientist who has obtained a PhD in Biochemistry from Lund University in Sweden and also completed a Post Doc at RPI in Dr. Cramer's group. Currently, he serves as an Associate Principal Scientist in Bioprocess Drug Substance and Commercialization at Merck. With over a decade of experience in the pharmaceutical industry, Tiago has worked for 3 years at Novo Nordisk and 7 years at Merck. He has an impressive track record with numerous published manuscripts, patents, and international awards. Throughout his career, Tiago has focused on various biomolecules such as nucleic acids, enzymes, antibodies, and vaccines, with a specific emphasis on process development and smart processing. His background in biochemistry equips him with the ability to apply a deep molecular understanding to enhance process design and develop advanced control strategies in the era of digitalization.

Presently, Tiago has the privilege of leading a dedicated team that is at the forefront of implementing next-generation technologies. Their primary goal is to drive necessary transformations during the commercialization phase, aiming to establish more robust, efficient, faster, and advanced process development and characterization using cutting-edge methods and technologies like digital twins. The utilization of digital twins can elevate process control strategies to new levels. The ongoing digital transformation pursued by Tiago and his team seeks to expedite the deployment of drugs, minimize errors and costs, and accelerate the delivery of medicines to patients. These efforts are expected to play a substantial role in shaping the future of drug development and manufacturing processes through the power of digital innovation.

Agenda Sessions

  • Digital Transformation: Accelerating Process Development and Enhancing Control Strategies